Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Shares Issued (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Shares Issued data on record, last reported at -$134.8 million in Q3 2025.

  • For Q3 2025, Shares Issued fell 41.88% year-over-year to -$134.8 million; the TTM value through Sep 2025 reached -$1.5 million, up 98.37%, while the annual FY2024 figure was $1.8 million, 82.23% up from the prior year.
  • Shares Issued reached -$134.8 million in Q3 2025 per TARS's latest filing, down from -$354000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $135.1 million in Q1 2025 and bottomed at -$134.8 million in Q3 2025.
  • Average Shares Issued over 5 years is $200066.7, with a median of $17000.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: crashed 33743.44% in 2022, then skyrocketed 16748.5% in 2025.
  • A 5-year view of Shares Issued shows it stood at $221000.0 in 2021, then plummeted by 33743.44% to -$74.4 million in 2022, then plummeted by 32.33% to -$98.4 million in 2023, then surged by 98.43% to -$1.5 million in 2024, then plummeted by 8617.4% to -$134.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$134.8 million in Q3 2025, -$354000.0 in Q2 2025, and $135.1 million in Q1 2025.